Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TUSSAL 35,4 MG JARABE EN SOBRES - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/TUSSAL 35,4 MG JARABE EN SOBRES

Approved

STANDARD

TUSSAL 35,4 MG JARABE EN SOBRES

Kern Pharma S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Apr 25, 2024
Approval ID: 62362e2b9da1a92b
Company: Kern Pharma S.L.
Type: Standard

Approval Details

Approval Id: 62362e2b9da1a92b
Drug Cima Aemps Name: TUSSAL 35,4 MG JARABE EN SOBRES
Register Number: 89519
Holder Company Name: Kern Pharma S.L.
Marketing Company Name: Kern Pharma S.L.
Holder Company Detail Path: /organization/kern-pharma-s-l
Marketing Company Detail Path: /organization/kern-pharma-s-l
Authorization Date: 2024-04-25
Dosage Form: JARABE EN SOBRE
Dose: 35,4 mg
Route Of Administration: VÍA ORAL
Prescription Type: Sin Receta
Commercialized: Yes
Company Name: Kern Pharma S.L.
Company Detail Path: /organization/kern-pharma-s-l

Company Information

Pharmaceutical Company Name: Kern Pharma S.L.
Country Name: Dominican Republic

Active Ingredients

CLOPERASTINA FENDIZOATO

35,4 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Apr 25, 2024

Approval ID

62362e2b9da1a92b

Type

Standard

Back to CIMA-AEMPS Approvals